Mirtazapina Refta (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Refta, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Refta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used to treat depressive disorders by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depression with insomnia: promotes sleep and alleviates nighttime restlessness. - Depression with anxiety: helps lessen anxiety associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation: pronounced drowsiness, especially after the first doses. - Increased appetite: often leading to weight gain. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headed sensation on standing. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Serotonin syndrome: potentially life‑threatening when combined with other serotonergic agents. - Abnormal liver tests: elevated transaminases indicating hepatic stress. - Hematologic abnormalities: neutropenia or thrombocytopenia.

When prescribing mirtazapine, clinicians should consider several safety measures.

- Weight monitoring: observe for significant weight gain. - Suicidal ideation: assess risk especially at treatment initiation. - Hepatic function: adjust dose in severe liver impairment. - Discontinuation: taper gradually to avoid withdrawal symptoms. - Concomitant CNS depressants: use with caution due to additive sedation. - Store at room temperature: keep in the original packaging, protect from moisture.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic antidepressants: may precipitate serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce mirtazapine concentrations.